Results 71 to 80 of about 19,412 (203)

Response to osimertinib treatment.

, 2019
Response to osimertinib treatment.
Xibin Qiu (673998), Tongyu Lin (419484), Yabing Cao (673996), Guangli Xiao (673997), Hao Hu (111737)   +4 more
core   +1 more source

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Journal of Hematology & Oncology, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
Kai Fu, Fachao Xie, Fang Wang, Liwu Fu
doaj   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source

Magnetothermal‐responsive drug release bone cement based on EGFR‐mutated lung cancer bone metastases

VIEW, EarlyView.
A novel magnetothermal‐responsive bone cement was developed by integrating PMMA/CPC/Osimertinib matrix with Fe3O4@SiO2@Zol nanomaterials. This dual‐drug system achieves controlled release, combining excellent mechanical properties with potent anti‐tumor activity and bone regulation for treating EGFR‐mutated LC‐BoM.
Kandi Xu, Kai Li, Hao Wang, Lishu Zhao, Xinyue Liu, Yujin Liu, Li Ye, Wengang Zhang, Zhimin Chen, Xuyang Chen, Yujie Li, Qianqian Zhang, Wencheng Zhao, Xuebin Zheng, Yu Chen, Yayi He   +15 more
wiley   +1 more source

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

, 2017
Mariacarmela Santarpia,1 Alessia Liguori,1 Niki Karachaliou,2 Maria Gonzalez-Cao,3 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Giuseppe Altavilla,1 Rafael Rosell3–5 1Medical Oncology Unit, Department of Human ...
Rosell R, D'Aveni A, Daffinà MG, Marabello G, Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Altavilla G   +8 more
core  

Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In a multi‐center Canadian cohort of 577 patients with advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with first/second‐generation TKIs, Asian ancestry and female sex predicted longer survival, while the L858R mutation predicted shorter survival.
Heather Halperin, Amanda J. W. Gibson, Ali Hussein, Mike Sung, Pascale Tomasini, Michelle Dean, Jennifer H. Law, Cheryl Ho, Vishal Navani, Natasha B. Leighl, Desiree Hao   +10 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, EarlyView.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis

MedComm
Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in lung adenocarcinoma (LUAD), but the underlying mechanisms are still not fully understood.
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu   +5 more
doaj   +1 more source

Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies

Cancer Science, EarlyView.
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang, Junyi Xiong, Li Ying, Yanyang Zeng, Ziqiang Ouyang, Mei Liu, Meihua Li   +6 more
wiley   +1 more source